Meanwhile, the Scd inhibitor aramchol was reported to significantly alleviate liver fibrosis in NASH patients61 and is now awaiting the phase 3 study for formulation improvement (NCT04104321).62 Here, SCD is linked to metabolic dysfunction-associated steatohepatitis.